Biotechnology
Medical
Biopharmaceutical

Alnylam Pharmaceuticals

$80.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.32 (2.96%) Today
$0.00 (0.00%) As of 4:08 PM EDT after-hours

Why Robinhood?

You can buy or sell ALNY and other stocks, options, ETFs, and crypto commission-free!

About ALNY

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. Read More The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Employees
1,065
Headquarters
Cambridge, Massachusetts
Founded
2002
Market Cap
8.97B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
856.61K
High Today
$81.01
Low Today
$78.77
Open Price
$78.77
Volume
481.27K
52 Week High
$124.22
52 Week Low
$60.27

Collections

Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Health
Therapy
Technology
US

ALNY Earnings

-$2.28
-$1.92
-$1.56
-$1.20
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$1.86 per share
Actual
-$1.83 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.